BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Up 4.7% - Should You Buy?

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) shares shot up 4.7% during trading on Monday . The company traded as high as $7.75 and last traded at $7.75. Approximately 1,648,389 shares traded hands during mid-day trading, a decline of 41% from the average session volume of 2,793,625 shares. The stock had previously closed at $7.40.

Analyst Upgrades and Downgrades

BCRX has been the topic of several recent research reports. Needham & Company LLC reiterated a "buy" rating and issued a $15.00 price target on shares of BioCryst Pharmaceuticals in a report on Thursday, April 10th. Royal Bank of Canada reiterated an "outperform" rating and set a $11.00 price target on shares of BioCryst Pharmaceuticals in a research report on Friday, April 11th. Wedbush initiated coverage on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. They issued an "outperform" rating and a $15.00 price objective on the stock. JMP Securities reaffirmed a "market outperform" rating and set a $18.00 target price on shares of BioCryst Pharmaceuticals in a report on Friday, January 31st. Finally, Evercore ISI increased their price target on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an "outperform" rating in a research note on Monday, January 13th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $15.57.

BioCryst Pharmaceuticals Stock Up 2.1 %

The firm has a fifty day simple moving average of $7.72 and a 200-day simple moving average of $7.75. The company has a market capitalization of $1.75 billion, a P/E ratio of -13.75 and a beta of 1.75.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last announced its quarterly earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.06). The business had revenue of $131.50 million for the quarter, compared to analysts' expectations of $126.64 million. During the same quarter in the prior year, the firm posted $0.28 earnings per share. The business's quarterly revenue was up 40.8% on a year-over-year basis. On average, sell-side analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current fiscal year.

Institutional Trading of BioCryst Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of BCRX. Vanguard Group Inc. raised its position in BioCryst Pharmaceuticals by 7.8% in the 4th quarter. Vanguard Group Inc. now owns 21,890,422 shares of the biotechnology company's stock valued at $164,616,000 after buying an additional 1,583,826 shares during the last quarter. Caligan Partners LP raised its holdings in shares of BioCryst Pharmaceuticals by 16.0% in the fourth quarter. Caligan Partners LP now owns 2,995,932 shares of the biotechnology company's stock valued at $22,529,000 after purchasing an additional 412,347 shares during the last quarter. Two Sigma Advisers LP lifted its position in shares of BioCryst Pharmaceuticals by 14.6% in the fourth quarter. Two Sigma Advisers LP now owns 2,499,812 shares of the biotechnology company's stock worth $18,799,000 after purchasing an additional 318,800 shares in the last quarter. Northern Trust Corp boosted its holdings in BioCryst Pharmaceuticals by 7.7% during the fourth quarter. Northern Trust Corp now owns 2,004,911 shares of the biotechnology company's stock worth $15,077,000 after purchasing an additional 143,986 shares during the last quarter. Finally, Eversept Partners LP grew its position in BioCryst Pharmaceuticals by 269.9% in the fourth quarter. Eversept Partners LP now owns 1,980,312 shares of the biotechnology company's stock valued at $14,892,000 after purchasing an additional 1,444,907 shares in the last quarter. Institutional investors and hedge funds own 85.88% of the company's stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.